Amoebiasis due to Entamoeba histolytica

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:67A06.0A06.1A06.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Amoebiasis due to Entamoeba histolytica is an infectious parasitic disease caused by the protozoan parasite Entamoeba histolytica. It is not a genetic disorder but rather an acquired infection transmitted through the fecal-oral route, typically via contaminated water or food. The disease is most prevalent in tropical and subtropical regions with poor sanitation. Approximately 90% of infections are asymptomatic, but the parasite can cause significant illness when it invades the intestinal wall or spreads to other organs. The disease primarily affects the gastrointestinal system, most commonly the colon, where it causes amoebic colitis characterized by bloody diarrhea (amoebic dysentery), abdominal pain, cramping, and tenderness. The parasite can erode through the intestinal mucosa, forming characteristic flask-shaped ulcers. In more severe cases, Entamoeba histolytica can spread hematogenously to the liver, causing amoebic liver abscess, which presents with right upper quadrant pain, fever, and hepatomegaly. Less commonly, the infection can disseminate to the lungs, brain, or other organs, leading to potentially life-threatening complications including amoebic lung abscess, cerebral amoebiasis, or cutaneous amoebiasis. Treatment depends on the clinical presentation. Invasive amoebiasis (symptomatic intestinal disease or extraintestinal disease) is treated with metronidazole or tinidazole as tissue-active agents, followed by a luminal agent such as paromomycin or diloxanide furoate to eliminate cysts remaining in the intestine. Asymptomatic carriers harboring cysts should also be treated with a luminal agent to prevent transmission and potential future invasive disease. Large liver abscesses may occasionally require percutaneous drainage. With appropriate treatment, the prognosis is generally good, though fulminant colitis and ruptured liver abscess carry significant mortality. Prevention relies on improved sanitation, safe water supply, and proper food hygiene.

Clinical phenotype terms— hover any for plain English:

Gastrointestinal dysmotilityHP:0002579Protracted diarrheaHP:0004385Bloody diarrheaHP:0025085Abnormal pericardium morphologyHP:0001697Constrictive pericarditisHP:0002563Deep venous thrombosisHP:0002625
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Amoebiasis due to Entamoeba histolytica.

View clinical trials →

No actively recruiting trials found for Amoebiasis due to Entamoeba histolytica at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Amoebiasis due to Entamoeba histolytica community →

No specialists are currently listed for Amoebiasis due to Entamoeba histolytica.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Amoebiasis due to Entamoeba histolytica.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Amoebiasis due to Entamoeba histolyticaForum →

No community posts yet. Be the first to share your experience with Amoebiasis due to Entamoeba histolytica.

Start the conversation →

Latest news about Amoebiasis due to Entamoeba histolytica

No recent news articles for Amoebiasis due to Entamoeba histolytica.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Amoebiasis due to Entamoeba histolytica

What is Amoebiasis due to Entamoeba histolytica?

Amoebiasis due to Entamoeba histolytica is an infectious parasitic disease caused by the protozoan parasite Entamoeba histolytica. It is not a genetic disorder but rather an acquired infection transmitted through the fecal-oral route, typically via contaminated water or food. The disease is most prevalent in tropical and subtropical regions with poor sanitation. Approximately 90% of infections are asymptomatic, but the parasite can cause significant illness when it invades the intestinal wall or spreads to other organs. The disease primarily affects the gastrointestinal system, most commonly